APOTEA

Apotea will release figures for the quarter ended 30 June 2026 on 17 July 2026. Three analysts expect on average earnings of SEK 0.710 per share (previous year SEK 0.690) and revenue of SEK 2.01 billion, an increase of 10.28% compared with the previous year. For the current fiscal year, consensus estimates are SEK 2.71 earnings per share (previous year SEK 2.20) and SEK 8.07 billion in revenue (previous year SEK 7.20 billion). » More on finanzen.net

Apotea reports a 10.5% sales increase in Q1 2025 to SEK 1.937 billion and an operating result of SEK 101 million with a margin of 5.2%. Gross margin was 28.3% and net cash position SEK 105 million. Management cites expansion into Norway, platform modernization and higher utilization at the Varberg logistics centre (54%) as drivers; future CapEx is expected to decline. Investor reaction: shares rose about 13.7% premarket. Risks: increased impairments, a slightly lower inventory turnover and intense competition. » More on de.investing.com

Apotea increased Q4 2025 sales by 7% to SEK 1,854m and full-year sales by 10.1% to SEK 7,203m. The Q4 EBIT margin fell to 1.3%, well below expectations, accompanied by a declining gross margin. The company emphasized strategic expansion into Norway, AI initiatives, and plans to reduce investments by SEK 50–70m annually, and proposed a dividend. After the results the stock rose about 5% pre-market, with investors showing confidence despite margin pressure. » More on de.investing.com